![\"A](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/05\/https:\/\/media.zenfs.com\/en\/aol_the_motley_fool_392\/29026e48fe6d9db6376089f6259b946f.jpeg\"\/)
<\/p>\n
A man holding money who looks like he is considering a decision.<\/p>\n
Image source: Getty Images.<\/p>\n
Kailera’s potential after the IPO<\/p>\n
According to Morgan Stanley research, the GLP-1 drug market<\/a>, targeted at weight loss, could reach $190 billion by 2035 — double 2025 levels.<\/p>\n Kailera is building out a weight-loss drug pipeline with both injectables and pills, with four candidates in various trial stages. Its lead-drug candidate, the once-weekly injectable Ribupatide, is in phase 3 trials. The company says it “has the potential to be a category-leading treatment for people living with obesity.”<\/p>\n The risks of biotech investing<\/p>\n Given the lack of new biotech offerings<\/a> over the last few years, Kailera offers a fresh opportunity. Unlike some other companies in the space, it also has at least one drug candidate that is further along in clinical trials.<\/p>\n Still, this is a notoriously risky sector, especially when investing in a company without any commercial products. There’s no guarantee Ribupatide, or any of the drugs Kailera is working on, will be approved.<\/p>\n This is an investment geared toward more aggressive investors who are prepared to handle setbacks and stumbling blocks and believe the rewards will eventually outweigh the risks.<\/p>\n Should you buy stock in Kailera Therapeutics right now?<\/p>\n Before you buy stock in Kailera Therapeutics, consider this:<\/p>\n The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks<\/a> for investors to buy now\u2026 and Kailera Therapeutics wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you\u2019d have $469,293!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,381,332!*<\/p>\n Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 993% \u2014 a market-crushing outperformance compared to 207% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n See the 10 stocks \u00bb<\/a><\/p>\n *Stock Advisor returns as of May 16, 2026.<\/p>\n Jack Delaney<\/a> has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Key Points The GLP-1 drug market could be worth $190 billion by 2035. Kailera Therapeutics has several weight-loss…\n","protected":false},"author":2,"featured_media":83956,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[44737,10689,272,1442,8628,3388],"class_list":["post-83955","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-biotech-sector","tag-ipo","tag-novo-nordisk","tag-obesity-treatment","tag-therapeutics","tag-weight-loss-drug"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116585040814870931","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/83955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=83955"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/83955\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/83956"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=83955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=83955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=83955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}